Synthesis of Quinazolines as Tyrosine Kinase Inhibitors

被引：21

作者：

Srivastava, Sanjay K. ^{[1
]}

Kumar, Vivek ^{[1
]}

Agarwal, Shiv K. ^{[1
]}

Mukherjee, Rama ^{[1
]}

Burman, Anand C. ^{[1
]}

机构：

[1] Dabur Res Fdn, Ghaziabad 201010, UP, India

来源：

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY | 2009年 / 9卷 / 03期

关键词：

GROWTH-FACTOR RECEPTOR; ATP-BINDING-SITE; IRREVERSIBLE INHIBITORS; SELECTIVE INHIBITORS; LAVENDUSTIN-A; PDGF RECEPTOR; POTENT; DERIVATIVES; 4-ANILINOQUINAZOLINES; PHOSPHORYLATION;

D O I：

10.2174/1871520610909030246

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the present review, the discovery and development of quinazoline as tyrosine kinase inhibitors has been described. The synthesis of most potent quinazoline inhibitors of EGFR, VEGFR and PDGRF has been discussed. Structure activity relationship for quinazoline as tyrosine kinase inhibitors has been established. It was found that C-4, C-6 and C-7 positions in quinazoline are appropriate sites for designing new tyrosine kinase inhibitors. This review should help the medicinal chemist in designing more effective tyrosine kinase inhibitors.

引用

页码：246 / 275

页数：30

共 50 条

[31] The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015-2020
Liang, Xiaoxia
Yang, Qian
Wu, Pan
He, Changliang
Yin, Lizi
Xu, Funeng
Yin, Zhongqiong
Yue, Guizhou
Zou, Yuanfeng
Li, Lixia
Song, Xu
Lv, Cheng
Zhang, Wei
Jing, Bo
BIOORGANIC CHEMISTRY, 2021, 113
[32] Merits and Pitfalls in the Characterization of Covalent Inhibitors of Bruton's Tyrosine Kinase
Harris, Christopher M.
Foley, Sage E.
Goedken, Eric R.
Michalak, Mark
Murdock, Sara
Wilson, Noel S.
SLAS DISCOVERY, 2018, 23 (10) : 1040 - 1050
[33] Pharmacophore Modeling of Tyrosine Kinase Inhibitors: 4-Anilinoquinazoline Derivatives
Chang, Yeong-Sheng
Yang, Ling-Ling
Wang, Bo-Cheng
JOURNAL OF THE CHINESE CHEMICAL SOCIETY, 2010, 57 (4B) : 916 - 924
[34] Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Gotink, Kristy J.
Verheul, Henk M. W.
ANGIOGENESIS, 2010, 13 (01) : 1 - 14
[35] Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Kristy J. Gotink
Henk M. W. Verheul
Angiogenesis, 2010, 13 : 1 - 14
[36] Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors
Reid, Terry-Elinor
Fortunak, Joseph M.
Wutoh, Anthony
Wang, Xiang Simon
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2016, 16 (13) : 1452 - 1462
[37] Bcr-Abl tyrosine kinase inhibitors- current status
Mughal, Anum
Aslam, Hafiz Muhammad
Khan, Aga Muhammad Hammad
Saleem, Shafaq
Umah, Ribak
Saleem, Maria
INFECTIOUS AGENTS AND CANCER, 2013, 8
[38] Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors
Hussain, Sahil
Mursal, Mohd
Verma, Garima
Hasan, Syed Misbahul
Khan, Mohemmed Faraz
EUROPEAN JOURNAL OF PHARMACOLOGY, 2024, 970
[39] Design and synthesis of a novel tyrosine kinase inhibitor template
Slavish, P. Jake
Jiang, Qin
Cui, Xiaoli
Morris, Stephan W.
Webb, Thomas R.
BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (09) : 3308 - 3316
[40] Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors from the Natural Origin: A Recent Perspective
Patel, Harun M.
Rane, Rajesh
Thapliyal, Neeta
Palkar, Mahesh
Shaikh, Mahamadhanif
Karpoormath, Rajshekhar
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2015, 15 (08) : 988 - 1011

← 1 2 3 4 5 →